Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Notice of Extraordinary General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no...
Karolinska Development divests its holding in the Danish dermatology company Henlez STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development...
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01 STOCKHOLM, SWEDEN...
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of...
Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 STOCKHOLM...
Interim Report - January-June 2024 STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator STOCKHOLM, SWEDEN –...
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone STOCKHOLM, SWEDEN...
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection...
Karolinska Development invests in BOOST Pharma, expanding its portfolio STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq...
Karolinska Development’s Annual General Meeting 2024 STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development”...
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC STOCKHOLM, SWEDEN – May 8...
Interim Report - January-March 2024 STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...
Notice of Annual General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048...
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관